Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 003

Drug Profile

TAK 003

Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda Pharmaceuticals USA; Dengue vaccine tetravalent - Takeda Pharmaceuticals USA; DENVax™; Needle-free dengue vaccine; QDENGA; Qdenga; TAK-003; TDV - Takeda Pharmaceuticals USA; Tetravalent dengue vaccine - Takeda Pharmaceuticals USA

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda Pharmaceuticals USA
  • Class Attenuated vaccines; Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dengue

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Dengue in Colombia (SC, Injection)
  • 01 Feb 2024 Registered for Dengue (In adolescents, In children, Prevention) in Colombia (SC) before February 2024 (Takeda pipeline; February 2024 )
  • 04 Oct 2023 Launched for Dengue (In adolescents, In children, Prevention, In adults) in Indonesia, Brazil, European Union, Norway, Liechtenstein, Iceland (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top